Navigation Links
Sensus Healthcare Announces the Formation of a Medical Advisory Board
Date:2/17/2011

BOCA RATON, Fla., Feb. 17, 2011 /PRNewswire/ -- Sensus Healthcare has announced the formation of a Medical Advisory Board (MAB). Accepting to Chair this Board as Medical Director is Dr. Armand B. Cognetta, distinguished Dermatologist and founder of Dermatology Associates of Tallahassee, Florida. Dr. Cognetta is recognized as a leader and innovator in his field. Dr. Cognetta will provide clinical guidance and patient advocacy in the ongoing development of the Company's leading Superficial Radiotherapy product platform, the SRT-100™, and also lead the Company's multi-disciplinary Medical Advisory Board in providing Sensus with clinical, ethical, and scientific counseling on the development of its future products and services. Joining Dr. Cognetta on his Board is a very distinguished and experienced panel of thought leaders in the treatment of skin cancer using Photon X-Ray technology. They are Dr. Gary Monheit, Dermatologist, Total Skin and Beauty, Birmingham AL; Dr. Domenico Valente, Dermatologist, Dermatology, Laser & Plastic Surgery, LLP of Plainview, NY; Dr. David Kent, Dermatologist, Dermatologic Surgery Specialists, PC, Macon GA; Dr. William Mendenhall, Radiation Oncologist, Chairman, Department of Radiation Oncology, University of Florida, Shands Teaching Hospital, Gainesville, FL; and Dr. Angela Abbatecola, Geriatric Medicine Specialist, Italian National Research Center on Aging, Ancona, Italy.

(Logo: http://photos.prnewswire.com/prnh/20110124/FL34943LOGO)

"I am pleased to accept the medical directorship with Sensus Healthcare and lead its Medical Advisory Board. I am a firm believer in providing patients with all available treatment options, thus delivering the most optimal therapy for every patient. It is the duty of a physician to discuss and design a treatment plan with their patient, which takes into account not only the disease but the physical health and well-being of the patient. In the case of basal cell and squamous cell carcinoma, as patients age and have one or more medical problems or are frail, non-surgical alternatives need to be explored. Photon RT is a therapeutic alternative to surgery or electron beam in elderly patients with certain tumor subtypes and locations. This is a time-honored, non-surgical modality which can be highly efficacious in select skin cancers yet still be extremely cost effective when compared to surgery or electron beam therapy. I am very optimistic in what the future holds in developing this technology to its fullest potential and the possibilities for our clinical community and patients." –Dr. Armand Cognetta (Medical Director, Sensus Healthcare)

"We are very excited to have the opportunity to collaborate with such a distinguished panel of experienced clinical experts on the subject of skin cancer treatment. We have a common objective; to provide patients and their physicians the choices that produce proven outcomes." –Joseph C. Sardano (President & CEO, Sensus Healthcare)

About Sensus Healthcare:Sensus Healthcare specializes in making proven non-melanoma skin cancer solutions more accessible to patients. Our dedicated superficial radiation therapy (SRT) systems are designed specifically to provide an alternative to surgical procedures for basal cell and squamous cell carcinomas. Our mobile, compact SRT-100™ systems are used widely by oncologists and dermatologists to bring non-melanoma skin cancer treatment to more patients in more settings. We also offer a professional skin care line, Sensus Skin Solutions™, through our physician SRT-100™ users for their patients.Contact:Vicky PerezPublic Relations561-922-5808 Ext 108vicky@sensushealthcare.com
'/>"/>

SOURCE Sensus Healthcare
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sensus Healthcare Announces New Professional Skin Care Line - Sensus Skin Solutions™
2. Sensus Healthcare Announces Strategic Partnership With Flagship Solutions Group
3. Genomic Health Reports Favorable Commentary on Value of Multigene Assays From the St. Gallen Expert Consensus Meeting on the Primary Treatment of Early Breast Cancer
4. GPhA Statement on the Introduction of the Bipartisan Biogenerics Consensus Bill: Promoting Innovation and Access to Life-Saving Medicine Act
5. New consensus on work-related asthma
6. Shionogi-ViiV Healthcare Starts Phase III Trial for 572-Trii Fixed-Dose Combination HIV Therapy
7. Anthera Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
8. Biodel Inc. to Present at 29th Annual JPMorgan Healthcare Conference on January 13th, 2011
9. Orexigen® Therapeutics to Present at JP Morgan Healthcare Conference
10. Cellular Dynamics International to Present at 29th Annual JPMorgan Healthcare Conference
11. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... -- Research and Markets has announced the ... report to their offering. ... The study scope ... plasmids, chassis organisms, synthetic cells, production systems), enabling technologies ... and specialty media) and enabled technologies (biofuels, chemicals, pharmaceuticals, ...
(Date:2/16/2017)... HOLLISTON, Mass. , Feb. 16, 2017   ... or the "Company"), a biotechnology company developing bioengineered organ ... the esophagus, bronchus and trachea, announced today the closing ... offering of 20,000,000 shares of common stock and warrants ... gross proceeds of $8.0 million. The offering was priced ...
(Date:2/16/2017)... , Feb. 16, 2017 UCHealth ( ... to utilize LungDirect for pulmonary nodule patient management. In ... nodule, or a spot on the lung, UCHealth looks ... on manual data entry. Stephanie Brown, ... tracking my nodule patients with an Excel spreadsheet, which ...
(Date:2/16/2017)... HACKENSACK, N.J. , Feb. 16, 2017  Champions ... engaged in the development and sale of advanced technology ... of oncology drugs, today announced the addition of new ... These new models will expand Champions, product ... cancer, head and neck cancer, AML, and non-small cell ...
Breaking Biology Technology:
(Date:1/25/2017)... NEW YORK , Jan. 25, 2017 /PRNewswire/ ... and Access Management (IAM) lifecycle is comprised of ... infrastructure for the purpose of maintaining digital identities ... enterprise resources and applications. There are significant number ... compliance from time to time by optimizing processes ...
(Date:1/19/2017)... , January 19, 2017 According to a new ... and Forecast, 2014 - 2022," the global biometric sensor market is expected to ... to 2022. In 2015, Asia-Pacific dominated the global market ... private sectors. Continue Reading ... ...
(Date:1/12/2017)... , Jan. 12, 2017  Trovagene, Inc. (NASDAQ: ... DNA (ctDNA) technologies, today announced that it has signed ... and the Middle East ...  This milestone marks the first wave of international distribution ... urine and blood samples. The initial partners ...
Breaking Biology News(10 mins):